CD34 (+) cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina

Patients with refractory angina who are suboptimal candidates for further revascularization have improved exercise time, decreased angina frequency, and reduced major adverse cardiac events with intramyocardial delivery of CD34(+) cells. However, the effect of CD34(+) cell therapy on health care exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Grace L., Henry, Timothy D., Povsic, Thomas J., Losordo, Douglas W., Garberich, Ross F., Stanberry, Larissa I., Strauss, Craig E., Traverse, Jay H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Human Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519768/
https://www.ncbi.nlm.nih.gov/pubmed/32531108
http://dx.doi.org/10.1002/sctm.20-0046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519768/
https://www.ncbi.nlm.nih.gov/pubmed/32531108
http://dx.doi.org/10.1002/sctm.20-0046

Ejemplares similares